e-Therapeutics has filed a patent for nucleic acid molecules designed for disease treatment or prevention. The claim specifies a unique structure with abasic nucleotides for inhibiting target gene expression. This innovation could potentially revolutionize therapeutic approaches. GlobalData’s report on e-Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on e-Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. e-Therapeutics's grant share as of January 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Nucleic acid molecules for disease treatment or prevention
The patent application (Publication Number: US20230407311A1) discloses a nucleic acid structure designed for inhibiting target genes. The nucleic acid includes a duplex region with a first strand partially complementary to RNA transcribed from the target gene and a second strand with two consecutive abasic nucleotides in the 5' terminal region. The second strand also features a reversed internucleotide linkage and specific 3'-5' linkages between the abasic nucleotides. Additionally, the nucleic acid may contain modified nucleotides, thermally destabilizing modifications, and phosphorothioate internucleotide linkages in specific regions.
Furthermore, the patent application describes the use of this nucleic acid structure in a pharmaceutical composition with a physiologically acceptable excipient. The composition aims to effectively inhibit target genes through the unique design of the nucleic acid. The inclusion of specific modifications and linkages enhances the stability and functionality of the nucleic acid structure. Overall, the patent application presents a novel approach to gene inhibition using a carefully engineered nucleic acid structure, offering potential applications in therapeutic interventions targeting specific genes.
To know more about GlobalData’s detailed insights on e-Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
